Kirkland, Cooley Pilot Bristol-Myers' $4B Cancer Drug Co. Buy
Bristol-Myers Squibb, advised by Kirkland, said Friday it plans to buy cancer drugmaker Turning Point Therapeutics Inc., guided by Cooley, in a deal that's worth $4.1 billion and comes as the...To view the full article, register now.
Already a subscriber? Click here to view full article